Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 3710 - 33rd Street NW CALGARY AB T2L 2M1 |
Tel: | 1-403-4557727 |
Website: | https://www.xortx.com |
IR: | See website |
Key People | ||
Allen W. Davidoff President, Chief Executive Officer, Director | James Neville Fairbairn Chief Financial Officer | Stacy Evans Chief Business Officer | Stephen Haworth Chief Medical Officer |
Business Overview |
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors. |
Financial Overview |
For the fiscal year ended 31 December 2023, XORTX Therapeutics Inc revenues was not reported. Net loss decreased 72% to $2.2M. Lower net loss reflects Research and development decrease of 64% to $2.4M (expense), Transaction costs on derivative warrant decrease from $926K (expense) to $0K, Share-based payments decrease of 75% to $121K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$5.22 to -$1.09. |
Employees: | 3 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2.32M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$8.11M as of Dec 31, 2023 |
Net annual income (TTM): | -$2.96M as of Dec 31, 2023 |
Free cash flow (TTM): | -$9.11M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,998,848 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |